Skip to content

Development of minimally invasive methodology for diabetyping to personalise treatment to realise remission and reversal of type 2 diabetes.

Development of minimally invasive methodology for diabetyping to personalise treatment to realise remission and reversal of type 2 diabetes. - 2DIAREM

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53345
Enrollment
57
Registered
2023-02-09
Start date
2024-03-18
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sugar Type 2 diabetes mellitus Type 2 diabetes mellitus

Interventions

During the 14 days of monitoring, participants are asked to undergo one OGTT and consume a standardized snack (Snelle Jelle) twice after an overnight fast. In between, the participants are asked to

Sponsors

TNO
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - - Diagnosed with (pre)diabetes type 2; o BMI >=27 kg/m2, including a heterogenous group of people with overweight/prediabetes (without glucose lowering medication), and/or type 2 diabetes with or without glucose lowering medication. - Aged 40 years or older - Able and willing to sign the informed consent form - Willing to comply with all study procedures

Exclusion criteria

Exclusion criteria: - Type 1 diabetes - Latent Autoimmune Diabetes (LADA) - Skin allergy, eczema or known sensitivity for adhesives - History of bariatric weight loss surgery - Planned (bariatric) surgery during the 3 weeks monitoring period with the CGM - Active cancer or chemotherapy or radiation within 2 years prior to participation - A condition that would need an MRI during the 3 weeks monitoring period with the CGM - Planned holiday during the 3 week GCM monitoring period - (Night)shiftworkers - Pregnancy and lactation - Chronic medical condition, treatment, or medication other than diabetes that may affect glucose metabolism (HIV diagnosis, use of steroids or immunosuppressive drugs, etc.) - 4 or more alcoholic drinks per day on a regular basis or use of recreational drugs

Design outcomes

Primary

MeasureTime frame
The objective of this study is to develop and evaluate algorithms predicting the different diabetypes and the underlying indices (diabetyping) with minimally invasive technology based on capillary sampling using and multi-day CGM with OGTT.

Secondary

MeasureTime frame
The secondary objective is to develop and evaluate minimally invasive diabetyping technology with algorithms based on capillary sampling, venous blood sampling and multi-day CGM upon a standardized snack under real-world conditions.

Countries

Netherlands

Contacts

Public ContactR.J.M. Kamstra

TNO

kristel.kamstra@tno.nl0611873786

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Mar 20, 2026